In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 38 for your search:
Drug:  veliparib
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M14-011, 2013-002377-21, NCT02032277

2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M11-089, 2013-005020-42, NCT02106546

3.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-00312, MAYO-MC0861, 09-000742, CDR0000657976, MC0861, 8329, P30CA015083, U01CA069912, NCT01012817

4.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02661, GOG-0076HH, CDR0000693745, U10CA027469, NCT01281852

5.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02583, CDR0000697580, 10-174, 8818, U01CA069856, P30CA008748, MSKCC-10174, NCT01326702

6.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02590, CDR0000700033, 11-02-068, 8853, P30CA013330, N01CM62204, AECM-11-02-068, NCT01351909

7.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02592, CHNMC-PHII-111, CDR0000701003, PHII-111, S1206, 8811, U10CA032102, N01CM62209, NCT01386385

8.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: NCI
Protocol IDs: NCI-2012-00082, 12-C-0213, CDR0000717423, P12978, PBTC-033, U01CA081457, NCT01514201

9.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Veli-BRCA, NCT01472783

10.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LCCC 2009-608, NCT01489865

11.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01985, U10CA021115, ECOG-E2511, CDR0000736704, E2511, NCT01642251

12.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: VeTo, NCT01690598

13.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 097517, NCT01042379

14.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01379, CHNMC-PHII-96, CDR0000674384, PHII-96, 8264, N01CM00071, N01CM62203, N01CM00032, N01CM62209, N01CM00099, N01CM00038, N01CM00039, N01CM62201, P30CA033572, NCT01149083

15.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M12-895, 2011-002913-12, NCT01506609

16.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01149, CDR0000730114, UCCRC-IL057, 12-0109, 9012, U01CA070095, N01CM00071, N01CM00038, U01CA062491, N01CM00039, P30CA014599, IL057, NCT01576172

17.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-00864, CDR0000732189, MSKCC-12-045, IRB #12-045, 8993, N01CM00032, N01CM00071, U01CA069856, P30CA008748, 12-045, NCT01585805

18.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01130, CDR0000737062, 12-021, 9026, N01CM00039, U01CA070095, P30CA008748, NCT01638546

19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: M10-897, 2011-003618-18, NCT01657799

20.

Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 12G.376, 2012-47, NCT01818063

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 130105, 13-C-0105, NCT01827384

22.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00262, 050803, CDR0000600234, 7998, U01CA132194, U01CA099118, P30CA072720, CINJ-050803, NCT00740805

23.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-01472, CINJ-050810, CDR0000641433, U01CA062505, UPCI 08-121, U01CA099168, 08-121, 8282, P30CA047904, NCT00892736

24.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-03730, CDR0000656038, GOG-9923, U10CA027469, NCT00989651

25.

Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-01473, OSU-09100, CDR0000656393, 8472, N01CM00070, N01CM62207, P30CA016058, NCT01017640
1   
New Search